Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials-Reference-Cited by-同舟云学术

Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials

Published:2018-02 Issue:1 Volume:18 Page:63-70
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Li Ling,Pan Zhanyu

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference48 articles.

1. Is breast cancer survival improving?;Giordano;Cancer,2004

2. Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs;Chul;Mayo Clin Proc,2016

3. Practical methods for incorporating summary time-to-event data into meta-analysis;Tierney;Trials,2007

4. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over;Paridaens;J Clin Oncol,2000

5. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer;Namer;Eur J Cancer,2011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation;Cancer Imaging;2024-06-07

2. Nomograms Predict PFS and OS for SCLC Patients After Standardized Treatment: A Real-World Study;International Journal of General Medicine;2024-05

3. Randomized Phase III Trial Comparing Epirubicin/ Doxorubicin Plus Docetaxel and Epirubicin/ Doxorubicin Plus Paclitaxel as First Line Treatment in Women with Advanced Breast Cancer;Journal for Research in Applied Sciences and Biotechnology;2023-06-12

4. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer;Frontiers in Oncology;2023-05-02

5. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer;Cancer Treatment Reviews;2022-12